1. Home
  2. BPYPN vs SCLXW Comparison

BPYPN vs SCLXW Comparison

Compare BPYPN & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brookfield Property Partners L.P. 5.750% Cumulative Redeemable Perpetual Preferred Units Series 3

BPYPN

Brookfield Property Partners L.P. 5.750% Cumulative Redeemable Perpetual Preferred Units Series 3

N/A

Current Price

$13.52

Market Cap

0.0

Sector

Finance

ML Signal

N/A

Logo Scilex Holding Company

SCLXW

Scilex Holding Company

N/A

Current Price

$0.17

Market Cap

0.0

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BPYPN
SCLXW
Founded
N/A
N/A
Country
Bermuda
United States
Employees
30200
30
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BPYPN
SCLXW
Price
$13.52
$0.17
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
N/A
4.0K
Earning Date
N/A
03-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$55,152,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
22.02
52 Week Low
N/A
$0.18
52 Week High
N/A
$0.18

Technical Indicators

Market Signals
Indicator
BPYPN
SCLXW
Relative Strength Index (RSI) 50.42 53.52
Support Level $13.30 $0.07
Resistance Level $13.68 $0.19
Average True Range (ATR) 0.14 0.02
MACD 0.01 0.00
Stochastic Oscillator 40.74 84.00

Price Performance

Historical Comparison
BPYPN
SCLXW

About BPYPN Brookfield Property Partners L.P. 5.750% Cumulative Redeemable Perpetual Preferred Units Series 3

Brookfield Property Partners LP owns, operates, and invests in commercial properties in North America, Europe, Australia, and Brazil. The company focuses on being an owner and operator of real estate, providing investors with diversified exposure to some of the iconic properties and acquiring high-quality assets at a discount to replacement cost or intrinsic value. Its operating segment includes Core Office, Core Retail, LP Investments, and Corporate Segments. The company operates in various sectors such as the office sector, retail sector, industrial, multifamily, hospitality, triple net lease, and corporate sector. It generates a majority of revenue from the LP Investments segment.

About SCLXW Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: